Strategic Focus Target retinal disease pharma partnerships around wet AMD, NPDR, and DME leveraging AXPAXLI and ELUTYX technology, exploring co-development, licensing, or strategic investment opportunities.

Clinical Momentum Leverage ongoing Phase 3 trials for wet AMD to position for collaborations with CROs, contract manufacturers, and patient access programs, aligning with potential accelerators or royalty arrangements.

Commercial Leadership Leverage newly appointed Global Chief Commercial Officer to build a scalable commercial strategy, identify early market access needs, and establish payer engagement opportunities for novel ocular therapies.

Industry Engagement Capitalize on recent conferences and investor events (Macula Society, EURETINA, Summit 2026) to generate partner prospects, co-marketing ventures, and strategic visibility among retinal specialists and biotech investors.

Financial Signals With mid market revenue range and ongoing litigation context, pursue risk-aware partnerships with co-funding, milestone-based agreements, and defense-ready IP and competitive landscape analyses to attract interested buyers or licensees.